Methotrexate for induction of remission in refractory Crohn's disease (Q24245655)

https://api.crossref.org/works/10.1002%2F14651858.CD003459.PUB2

Low-dose oral methotrexate in refractory inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003459.PUB2

Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003459.PUB2

Methotrexate in refractory Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003459.PUB2

Pharmacokinetics of subcutaneous methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003459.PUB2

Administration of medications via the intramuscular route: an integrative review of the literature and research-based protocol for the procedure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003459.PUB2

Prognosis in Crohn's disease--based on results from a regional patient group from the county of Copenhagen

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003459.PUB2

Systemic and intestinal pharmacokinetics of methotrexate in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003459.PUB2

A simple index of Crohn's-disease activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003459.PUB2

Drawing up and administering intramuscular injections: a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003459.PUB2

Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003459.PUB2

Methotrexate for the Treatment of Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003459.PUB2

Pharmacokinetics of methotrexate administered by intramuscular and subcutaneous injections in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003459.PUB2

7 January 2021

Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003459.PUB2

7 January 2021

A randomized dose-response and pharmacokinetic study of methotrexate for refractory inflammatory Crohn's disease and ulcerative colitis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003459.PUB2

7 January 2021

Do patients with rheumatoid arthritis established on methotrexate and folic acid 5 mg daily need to continue folic acid supplements long term?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003459.PUB2

7 January 2021

Daily folate supplementation is adequate prophylaxis against methotrexate-induced nausea and vomiting and avoids the need for expensive anti-emetic prescription

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003459.PUB2

7 January 2021

6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003459.PUB2

7 January 2021

Methotrexate for the treatment of refractory Crohn's disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003459.PUB2

7 January 2021

6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003459.PUB2

7 January 2021